Onkos Surgical to distribute
Mölndal,
"We are pleased to partner with a world-class company like Onkos Surgical for the benefit of the US market. I'm convinced that together
Onkos Surgical was [The OPRA Implant System consists of an anchorage element
founded in 2015 fixture and a skin penetrating device abutment The
with a singular prosthetic leg is then attached directly to the abutment
focus on bringing via the OPRAT AXOR a prosthetic connection and safety
innovation to device]
musculoskeletal
oncologists and The OPRA™ Implant System consists of an anchorage element
the patients they (fixture) and a skin penetrating device (abutment). The
care for. Built prosthetic leg is then attached directly to the abutment
on a digital via the OPRAT™ AXOR™, a prosthetic connection and safety
platform, Onkos is device.-
an emerging leader
in the field of
personalized
orthopaedics.
With expertise in
personalized
surgical planning,
3D modeling and
the latest
advancements in 3D
printing, the
company has
developed a suite
of products
designed to reduce
complexity and
address the
clinical
challenges
associated with
tumor and complex
orthopedic
revision
surgery. Patrick
Treacy, Co-founder
and CEO said, "We
are delighted to
partner with Dr.
Rickard Brånemark,
a global expert
and leading
pioneer in the
field of
osseointegration.
revolutionizing
the field of bone
anchored
prosthetics and
given our focus on
limb salvage, the
OPRA™ technology
is complementary
to our portfolio
strategy. The
combined expertise
of both companies
will provide
surgeons with
greater access to
advanced bone
anchored
prosthetics and
provide patients
with meaningful
reconstructive
options."
Cautions Concerning Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "future," "believes," "expects," "may," "will," "can," "should," "potential," "estimates," "intends," "aims," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, delays potentially caused by the need for institutional review board approval and product training, distribution challenges, unexpected product efficacy and safety concerns, product or raw material availability and other supply constraints. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law.
The information in this press release is information that
About
About Onkos Surgical
Based in
Contact
CEO
+46 708 46 10 69
maria.lopez@integrum.se
www.integrum.se
SVP, Commercial Operations
Onkos Surgical
+1 (973) 264-5400
scurry@onkossurgical.com
www.onkossurgical.com
[An OPRA Implant System amputee user showing the connection of a standard prosthetic leg to the OPRA Implant System via the OPRA AXOR prosthetic connection and safety device]
An OPRA™ Implant System amputee user, showing the connection of a standard prosthetic leg to the OPRA™ Implant System via the OPRA™ AXOR™ prosthetic connection and safety device.
https://news.cision.com/integrum-ab/r/integrum-partners-with-onkos-surgical-to-further-drive-us-market-for-bone-anchored-prosthetics,c3013475
https://mb.cision.com/Main/17531/3013475/1177236.pdf
https://mb.cision.com/Public/17531/3013475/96e04f1fe8a30191_org.png
https://mb.cision.com/Public/17531/3013475/9b37592d78b6fedf_org.jpg
(c) 2020 Cision. All rights reserved., source